依达拉奉联合丹红注射液治疗急性脑梗死疗效的系统分析

目的:评价依达拉奉联合丹红注射液治疗急性脑梗死的疗效及安全性。方法:检索Cochrane,Pub Med,Med Line,Science Direct,CNKI,Wanfang和VIP(2000年1月—2014年12月),查找依达拉奉联合丹红注射液治疗急性脑梗死的随机对照试验,应用Rev Man 5.1做Meta分析。结果:共纳入25个随机对照实验。Meta分析结果显示:依达拉奉联合丹红注射液在治疗急性脑梗死有效率方面与对照组比较,其差异有统计学意义,[OR=4.15,95%CI(3.24,5.21)];神经功能缺损评分方面与对照组比较,其差异有统计学意义,[WMD=-3.75,95%CI(-4.53,-2.96)];日常生活能力评分方面与对照组比较,其差异有统计学意义,[WMD=14.40,95%CI(12.97,15.83)]。结论:依达拉奉联合丹红注射液治疗急性脑梗死的疗效优于依达拉奉治疗组、丹红注射液治疗组及常规治疗组。

Edaravone Combined with Danhong Injection in Treating Acute Cerebral Infarction

Objective: To assess the effect and safety of edaravone combined with Danhong injection in treating acute cerebral infarction (ACI) by Meta-analysis. Method: Randomized control trials (RCTs) of edaravone combined with Danhong injection in treating ACI were retrieved from Cochrane Library, PubMed, MedLine, ScienceDirect, CNKI, Wanfang and VIP (from January 2000 to December 2014). The data was analyzed by using RevMan 5.1. Result: Twenty-five RCTs were included. The results showed that edaravone combined with Danhong injection had statistically significant differences compared with control group in the effective rate for ACI [OR=4.15, 95%CI (3.24, 5.21)], the neurological deficit scores [WMD=-3.75, 95%CI (-4.53, -2.96)] and the activities of daily living score [WMD=14.40, 95%CI (12.97, 15.83)]. Conclusion: Compared with edaravone treatment group, Danhong injection treatment group and routine treatment group, edaravone combined with Danhong injection has a better efficacy for ACI.